Sunesis Pharmaceuticals - Inspired to Make a Difference in Cancer Patients Lives.

Products in Development

Sunesis Products In Development

Vecabrutinib (SNS-062)
SNS-062 is a potent, reversible, non-covalent inhibitor of Bruton's tyrosine kinase (BTK). Vecabrutinib is being developed as a potential therapy for B-cell malignancies such as chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), lymphoplasmacytoid lymphoma/Waldenström's macroglobulinemia (LPL/WM), mantle cell lymphoma (MCL), and other lymphomas. Vecabrutinib does not interact with the cysteine residue, C481, within the kinase domain that is required for activity by approved and other emerging covalent BTK inhibitors. Because vecabrutinib is a selective, non-covalent inhibitor with a favorable pharmacokinetic profile, SNS-062 may provide differentiated opportunities for treatment of B-cell malignancies and other cancers.

SNS-510 (PDK1)
Phosphoinositide dependent protein kinase 1 (PDK1) is a key kinase that is critical for activation of the PI3K/AKT signaling pathway, which is essential for regulating cell growth, differentiation, survival and migration and is therefore frequently activated in cancer. In addition, SNS-510 inhibits other important signaling pathways, including NFKB and MAPK, by phosphoinositide-independent mechanisms.

TAK-580 (RAF)
TAK-580 (formerly called MLN2480) is an oral pan-RAF kinase inhibitor with a distinct molecular signature which has exhibited a promising preclinical profile. The MAPK pathway plays a key role in regulating cell proliferation and survival by integrating signals from various cell surface receptors. Signaling hyperactivation secondary to genetic aberrations affecting the mitogen-activated protein kinase (MAPK) pathway occurs frequently in several human tumors, and results in increased cell proliferation and survival. The RAF kinases (A-RAF, B-RAF and C-RAF) are key regulators of cell proliferation and survival within the MAPK pathway. Because of their central role in this hyperactivated MAPK signaling cascade, RAF kinases present as exciting candidate therapeutic targets for partner-directed development in solid tumor malignancies.

Vosaroxin is an anti-cancer quinolone derivative, or AQD - a class of compounds not used previously for the potential treatment of cancer that intercalates DNA and inhibits topoisomerase II. Vosaroxin is in clinical development through ongoing investigator-sponsored studies in myeloid malignancies.

We strongly believe that sharing ideas and advances with other scientists helps move the oncology treatment discipline forward. Sunesis scientists and leaders regularly present hypotheses and findings at conferences and symposia worldwide.

Download reprints of research and studies we have submitted to scientific and medical journals.